Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OMCL 
Omnicell Inc (OMCL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/13/2025: OMCL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Year Target Price $39.83
Year Target Price $39.83
| 3 | Strong Buy |
| 1 | Buy |
| 4 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 19.14% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.38B USD | Price to earnings Ratio 63.87 | 1Y Target Price 39.83 |
Price to earnings Ratio 63.87 | 1Y Target Price 39.83 | ||
Volume (30-day avg) 8 | Beta 0.78 | 52 Weeks Range 22.66 - 55.74 | Updated Date 06/30/2025 |
52 Weeks Range 22.66 - 55.74 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1.87% | Operating Margin (TTM) -4.31% |
Management Effectiveness
Return on Assets (TTM) 0.35% | Return on Equity (TTM) 1.73% |
Valuation
Trailing PE 63.87 | Forward PE 29.5 | Enterprise Value 1362196649 | Price to Sales(TTM) 1.21 |
Enterprise Value 1362196649 | Price to Sales(TTM) 1.21 | ||
Enterprise Value to Revenue 1.2 | Enterprise Value to EBITDA 13.76 | Shares Outstanding 46843600 | Shares Floating 45733411 |
Shares Outstanding 46843600 | Shares Floating 45733411 | ||
Percent Insiders 1.77 | Percent Institutions 104.6 |
Analyst Ratings
Rating 3 | Target Price 39.83 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Omnicell Inc
Company Overview
History and Background
Omnicell Inc. was founded in 1992. Initially focused on automated medication dispensing, it has grown through organic development and acquisitions to offer a broad portfolio of medication management solutions for healthcare facilities.
Core Business Areas
- Medication Management Systems: Automated medication dispensing systems for hospitals and pharmacies, aiming to improve accuracy, reduce errors, and enhance efficiency. This includes solutions for point-of-care dispensing, central pharmacy automation, and controlled substance management.
- Medication Adherence Solutions: Solutions designed to help patients take their medications as prescribed, including adherence packaging, telehealth services, and mobile apps.
- IV Automation: Automated IV compounding systems that streamline and standardize sterile compounding processes in hospital pharmacies. Aims to improve safety, accuracy and efficiency for IV medication preparation
- Supply Chain Solutions: Helps to streamline pharmaceutical supply chain management for healthcare facilities. Optimize their inventory management processes
Leadership and Structure
Randal W. Kirk is the current Interim CEO. The organizational structure consists of functional departments such as sales, marketing, research and development, operations, and finance, organized under executive leadership.
Top Products and Market Share
Key Offerings
- XT Series Automated Medication Dispensing System: Omnicell's flagship medication dispensing system that uses automation to provide accuracy and security. Market share data for this specific system is difficult to ascertain, but Omnicell is a leading player in the overall medication management automation market. Competitors include BD, Cerner, and Capsa Healthcare.
- Central Pharmacy Automation: Includes automated storage and retrieval systems, robotic dispensing systems, and inventory management software. The specific revenue generated from this solution isn't publicly disclosed, however, Omnicell competes with companies such as ARxIUM, ScriptPro and iRx.
- EnlivenHealth: Medication adherence platform that integrates with EHR systems and provides actionable insights to healthcare providers. The number of users and revenue generated from this product aren't publicly disclosed, but Omnicell is the market share leader. Their competitors include DrFirst, Allscripts, and ConnectiveRx.
Market Dynamics
Industry Overview
The healthcare technology industry is growing, driven by increasing demand for automation, medication safety, and cost containment. The market is highly competitive, with numerous players offering similar solutions.
Positioning
Omnicell Inc. is positioned as a leading provider of medication management solutions. Its competitive advantages include a broad product portfolio, established customer base, and a reputation for innovation. They are pushing toward end to end pharmacy management.
Total Addressable Market (TAM)
The global medication management market is expected to reach hundreds of billions of dollars. Omnicell is well positioned to capitalize on this growth by expanding its product offerings and geographic reach.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Established customer base
- Strong brand recognition
- Innovative solutions
- Recurring revenue stream from software and services
Weaknesses
- High debt levels
- Integration challenges from acquisitions
- Dependence on hospital capital spending
- High R&D expenditures
Opportunities
- Expanding into new markets
- Developing new solutions for medication adherence
- Leveraging data analytics to improve medication management
- Increasing demand for automation in healthcare
- Partnerships with larger healthcare systems
Threats
- Increased competition
- Price pressures from healthcare providers
- Regulatory changes
- Economic downturns
- Cybersecurity risks
Competitors and Market Share
Key Competitors
- BDX
- CERNER
- SYST
Competitive Landscape
Omnicell's advantages include its comprehensive product portfolio and focus on medication management. Disadvantages include its higher debt levels and integration challenges compared to larger, more diversified competitors.
Major Acquisitions
RxSafe
- Year: 2021
- Acquisition Price (USD millions): 275
- Strategic Rationale: Expanded Omnicell's portfolio of pharmacy automation solutions into the retail pharmacy market, enhancing its presence in medication adherence and retail pharmacy automation.
ReCept Pharmacy
- Year: 2021
- Acquisition Price (USD millions): 282
- Strategic Rationale: Enhanced Omnicell's capabilities in specialty pharmacy services, providing new solutions for medication management and adherence.
Growth Trajectory and Initiatives
Historical Growth: Omnicell has achieved growth through product innovation, market expansion, and strategic acquisitions.
Future Projections: Analyst projections suggest continued revenue growth for Omnicell, but profitability remains a key challenge. The company's success depends on its ability to manage costs, integrate acquisitions, and capitalize on market opportunities.
Recent Initiatives: Focus on medication adherence solutions, expansion of cloud-based offerings, and strategic partnerships with healthcare providers.
Summary
Omnicell is a leading provider of medication management solutions, benefiting from a broad product portfolio and established customer base. However, the company faces challenges including high debt levels and integration of acquired companies. Strategic initiatives focused on medication adherence and expansion into new markets offer growth potential. Profitability remains a key area of focus due to ongoing losses.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Omnicell Investor Relations
- Market Research Reports
- Financial News Articles
- Company SEC Filings
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. The analysis is based on publicly available data and analyst estimates, which are subject to change. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Omnicell Inc
Exchange NASDAQ | Headquaters Fort Worth, TX, United States | ||
IPO Launch date 2001-08-07 | Founder, Executive Chairman, President & CEO Mr. Randall A. Lipps | ||
Sector Healthcare | Industry Health Information Services | Full time employees 3620 | Website https://www.omnicell.com |
Full time employees 3620 | Website https://www.omnicell.com | ||
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.